German biotech company BioNTech SE has announced the start of its malaria project, which aims to develop safe, effective and sustainable malaria vaccine supply solutions in Africa.
BioNTech wants to build on its success in developing a Covid-19 vaccine (in conjunction with Pfizer) by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end on 2022.
